The Monsanto Company is still reeling from a March 2015 World Health Organization announcement that glyphosate was found to be a probable human carcinogen. The finding has sent Monsanto into damage control mode for months as millions of people have begun to scrutinize the company and its sordid history.
Now Monsanto is doing everything in its power in order to cast doubt on that declaration, even soliciting the help of its own consultants in order to present their own version of scientific review on glyphosate, the main ingredient in its best-selling weedkiller Roundup.
According to a new report from the website GMWatch, a 16-member panel assembled by Intertek Scientific & Regulatory Consultancy was expected to present findings to the annual meeting of the Society for Risk Analysis on Monday of this week and is hoping to publish its study at a later date.
The group, which was hired by Monsanto, is disputing the WHO International Agency for Research on Cancer’s findings on glyphosate. But their ties to Monsanto are raising red flags.
In total, 10 of the 16 scientists on the Intertek panel hired by Monsanto have consulted with the company in the past, and 2 others are former Monsanto employees, according to the GMWatch article which cited a roster published on Monsanto’s website.
The conflict-of-interest is reminding some of the journal Food & Toxicology and its appointment of a former Monsanto employee to its editorial board, which resulted in the retraction of a study that linked GMO feed to tumors in lab animals (one that was later republished in another peer reviewed journal).
The Monsanto-funded group is saying that some of the data used to declare glyphosate as a carcinogen was misinterpreted or incorrectly weighted, and that some other data on the chemical was ignored.
Glyphosate and Roundup are huge money-makers for Monsanto, especially since the company also produces genetically engineered crops that are designed to withstand the sprayings of these chemicals. What happens with the WHO moving forward could have a dramatic impact on its bottom line and future as a company.
For more on the situation and why some are concerned about why this could be an attack on independent science, check out the full article from GMWatch by clicking here.